Literature DB >> 21800072

Non-absorbed antibiotic for irritable bowel syndrome.

Brooks D Cash1.   

Abstract

Entities:  

Year:  2011        PMID： 21800072     DOI： 10.1007/s11894-011-0211-y

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


× No keyword cloud information.
  10 in total

1.  Rifaximin therapy for patients with irritable bowel syndrome without constipation.

Authors:  Mark Pimentel; Anthony Lembo; William D Chey; Salam Zakko; Yehuda Ringel; Jing Yu; Shadreck M Mareya; Audrey L Shaw; Enoch Bortey; William P Forbes
Journal:  N Engl J Med       Date:  2011-01-06       Impact factor: 91.245

2.  The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial.

Authors:  Mark Pimentel; Sandy Park; James Mirocha; Sunanda V Kane; Yuthana Kong
Journal:  Ann Intern Med       Date:  2006-10-17       Impact factor: 25.391

3.  Small intestinal bacterial overgrowth in patients with irritable bowel syndrome.

Authors:  Iris Posserud; Per-Ove Stotzer; Einar S Björnsson; Hasse Abrahamsson; Magnus Simrén
Journal:  Gut       Date:  2006-12-05       Impact factor: 23.059

4.  A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.

Authors:  M Camilleri; W Y Chey; E A Mayer; A R Northcutt; A Heath; G E Dukes; D McSorley; A M Mangel
Journal:  Arch Intern Med       Date:  2001-07-23

Review 5.  Abnormal breath testing in IBS: a meta-analysis.

Authors:  Eric D Shah; Robert J Basseri; Kelly Chong; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2010-05-14       Impact factor: 3.199

6.  Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci.

Authors:  H L DuPont; Z-D Jiang
Journal:  Clin Microbiol Infect       Date:  2004-11       Impact factor: 8.067

Review 7.  Functional bowel disorders.

Authors:  George F Longstreth; W Grant Thompson; William D Chey; Lesley A Houghton; Fermin Mearin; Robin C Spiller
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

8.  A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.

Authors:  H Nyhlin; C Bang; L Elsborg; J Silvennoinen; I Holme; P Rüegg; J Jones; A Wagner
Journal:  Scand J Gastroenterol       Date:  2004-02       Impact factor: 2.423

9.  Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.

Authors:  Janet Yang; Hyo-Rang Lee; Kimberly Low; Soumya Chatterjee; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2007-05-23       Impact factor: 3.199

10.  Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

Authors:  D A Drossman; W D Chey; J F Johanson; R Fass; C Scott; R Panas; R Ueno
Journal:  Aliment Pharmacol Ther       Date:  2008-11-04       Impact factor: 8.171
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.